CENESTIN

Cenestin Adverse Events Reported to the FDA Over Time

How are Cenestin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cenestin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cenestin is flagged as the suspect drug causing the adverse event.

Most Common Cenestin Adverse Events Reported to the FDA

What are the most common Cenestin adverse events reported to the FDA?

Breast Cancer Female	154 (33.19%)
Breast Cancer	97 (20.91%)
Breast Cancer Metastatic	8 (1.72%)
Ovarian Cancer	8 (1.72%)
Anxiety	7 (1.51%)
Breast Disorder	6 (1.29%)
Pain	6 (1.29%)
Drug Ineffective	4 (.86%)
Marital Problem	4 (.86%)
Myocardial Infarction	4 (.86%)
Vision Blurred	4 (.86%)
	Show More
Abdominal Distension	3 (.65%)
Abdominal Pain	3 (.65%)
Cerebrovascular Accident	3 (.65%)
Confusional State	3 (.65%)
Memory Impairment	3 (.65%)
Neoplasm Malignant	3 (.65%)
Oestrogen Receptor Assay Positive	3 (.65%)
Progesterone Receptor Assay Positiv...	3 (.65%)
Abdominal Discomfort	2 (.43%)
Abdominal Tenderness	2 (.43%)
Amnesia	2 (.43%)
Anorexia	2 (.43%)
Aphasia	2 (.43%)
Balance Disorder	2 (.43%)
Breast Cancer In Situ	2 (.43%)
Breast Tenderness	2 (.43%)
Cholelithiasis	2 (.43%)
Depression	2 (.43%)
Dizziness	2 (.43%)
Dysarthria	2 (.43%)
Endometrial Cancer Metastatic	2 (.43%)
Fatigue	2 (.43%)
Fluid Retention	2 (.43%)
Grand Mal Convulsion	2 (.43%)
Hepatic Steatosis	2 (.43%)
Hyperhidrosis	2 (.43%)
Incontinence	2 (.43%)
Libido Decreased	2 (.43%)
Lipid Metabolism Disorder	2 (.43%)
Medication Error	2 (.43%)
Metastases To Liver	2 (.43%)
Metastases To Lymph Nodes	2 (.43%)
Migraine	2 (.43%)
Nervous System Disorder	2 (.43%)
Photophobia	2 (.43%)
Psychomotor Hyperactivity	2 (.43%)
Speech Disorder	2 (.43%)
Tearfulness	2 (.43%)
Venous Thrombosis	2 (.43%)
Withdrawal Syndrome	2 (.43%)
Adverse Drug Reaction	1 (.22%)
Alopecia	1 (.22%)
Angina Pectoris	1 (.22%)
Arthralgia	1 (.22%)
Asthenia	1 (.22%)
Blood Cholesterol Increased	1 (.22%)
Blood Glucose Increased	1 (.22%)
Blood Potassium Decreased	1 (.22%)
Blood Pressure Decreased	1 (.22%)
Blood Pressure Increased	1 (.22%)
Bone Pain	1 (.22%)
Calcinosis	1 (.22%)
Chest Pain	1 (.22%)
Convulsion	1 (.22%)
Cutaneous Lupus Erythematosus	1 (.22%)
Cystitis	1 (.22%)
Decreased Appetite	1 (.22%)
Deep Vein Thrombosis	1 (.22%)
Diarrhoea	1 (.22%)
Disease Recurrence	1 (.22%)
Drug Effect Decreased	1 (.22%)
Drug Interaction	1 (.22%)
Dyskinesia	1 (.22%)
Dyspnoea	1 (.22%)
Dysuria	1 (.22%)
Erythema	1 (.22%)
Excoriation	1 (.22%)
Feeling Abnormal	1 (.22%)
Feeling Cold	1 (.22%)
Flushing	1 (.22%)
Gastric Disorder	1 (.22%)
Haemangioma	1 (.22%)
Headache	1 (.22%)
Heart Rate Increased	1 (.22%)
Hepatic Enzyme Increased	1 (.22%)
Hepatitis	1 (.22%)
Hot Flush	1 (.22%)
Hypersensitivity	1 (.22%)
Hypoaesthesia	1 (.22%)
Injury	1 (.22%)
Insomnia	1 (.22%)
Irritability	1 (.22%)
Lupus-like Syndrome	1 (.22%)
Malaise	1 (.22%)
Malignant Neoplasm Progression	1 (.22%)
Mental Disorder	1 (.22%)
Metastases To Abdominal Cavity	1 (.22%)
Metastases To Bone	1 (.22%)
Muscle Spasms	1 (.22%)
Myalgia	1 (.22%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Cenestin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cenestin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cenestin

What are the most common Cenestin adverse events reported to the FDA?

Breast Neoplasms Malignant And Unsp...	261 (56.25%)
Neurological	13 (2.8%)
Reproductive Neoplasms Female Malig...	11 (2.37%)
Gastrointestinal Signs	10 (2.16%)
Breast	8 (1.72%)
Anxiety Disorders	7 (1.51%)
Therapeutic And Nontherapeutic Effe...	7 (1.51%)
Endocrine Investigations	6 (1.29%)
Epidermal And Dermal Conditions	6 (1.29%)
Metastases	6 (1.29%)
Miscellaneous And Site Unspecified ...	6 (1.29%)
	Show More
Coronary Artery	5 (1.08%)
Mental Impairment	5 (1.08%)
Central Nervous System Vascular	4 (.86%)
Depressed Mood Disorders	4 (.86%)
Family Issues	4 (.86%)
Urinary Tract Signs	4 (.86%)
Vision	4 (.86%)
Appetite And General Nutritional	3 (.65%)
Cardiac And Vascular Investigations	3 (.65%)
Deliria	3 (.65%)
Embolism And Thrombosis	3 (.65%)
Headaches	3 (.65%)
Hepatic And Hepatobiliary	3 (.65%)
Movement Disorders	3 (.65%)
Psychiatric	3 (.65%)
Seizures	3 (.65%)
Skin Appendage Conditions	3 (.65%)
Vascular	3 (.65%)
Allergic Conditions	2 (.43%)
Bone Disorders	2 (.43%)
Electrolyte And Fluid Balance Condi...	2 (.43%)
Gallbladder	2 (.43%)
Infections - Pathogen Unspecified	2 (.43%)
Injuries	2 (.43%)
Lipid Metabolism	2 (.43%)
Medication Errors	2 (.43%)
Muscle	2 (.43%)
Ocular Sensory Symptoms	2 (.43%)
Sexual Dysfunctions, Disturbances A...	2 (.43%)
Tissue	2 (.43%)
Connective Tissue Disorders	1 (.22%)
Dental And Gingival Conditions	1 (.22%)
Exocrine Pancreas Conditions	1 (.22%)
Gastrointestinal Conditions	1 (.22%)
Gastrointestinal Motility And Defec...	1 (.22%)
Hepatobiliary	1 (.22%)
Injuries By Physical Agents	1 (.22%)
Joint	1 (.22%)
Lipid Analyses	1 (.22%)
Metabolic, Nutritional And Blood Ga...	1 (.22%)
Miscellaneous And Site Unspecified ...	1 (.22%)
Musculoskeletal And Connective Tiss...	1 (.22%)
Personality Disorders	1 (.22%)
Pulmonary Vascular	1 (.22%)
Renal Disorders	1 (.22%)
Respiratory	1 (.22%)
Sleep Disorders	1 (.22%)
Vulvovaginal Disorders	1 (.22%)
Water, Electrolyte And Mineral	1 (.22%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cenestin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cenestin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.